» Articles » PMID: 23863167

Pseudokinases from a Structural Perspective

Overview
Specialty Biochemistry
Date 2013 Jul 19
PMID 23863167
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The catalytic (C) subunit of PKA was the first protein kinase structure to be solved, and it continues to serve as the prototype for the protein kinase superfamily. In contrast, by comparing many active and inactive kinases, we developed a novel 'spine' concept where every active kinase is composed of two hydrophobic spines anchored to a hydrophobic F-helix. The R-spine (regulatory spine) is dynamically assembled, typically by activation loop phosphorylation, whereas the C-spine (catalytic spine) is completed by the adenine ring of ATP. In the present paper, we show how the spine concept can be applied to B-Raf, specifically to engineer a kinase-dead pseudokinase. To achieve this, we mutated one of the C-spine residues in the N-lobe (N-terminal lobe), Ala481, to phenylalanine. This mutant cannot bind ATP and is thus kinase-dead, presumably because the phenylalanine ring fills the adenine-binding pocket. The C-spine is thus fused. However, the A481F mutant is still capable of binding wild-type B-Raf and wild-type C-Raf, and dimerization with a wild-type Raf leads to downstream activation of MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] and ERK. The mutant requires dimerization, but is independent of Ras and does not require enzymatic activity. By distinguishing between catalytic and scaffold functions of B-Raf, we define kinases as being bifunctional and show that, at least in some cases, the scaffold function is sufficient for downstream signalling. Since this alanine residue is one of the most highly conserved residues in the kinome, we suggest that this may be a general strategy for engineering kinase-dead pseudokinases and exploring biological functions that are independent of catalysis.

Citing Articles

Drug resistance in targeted cancer therapies with RAF inhibitors.

Degirmenci U, Yap J, Sim Y, Qin S, Hu J Cancer Drug Resist. 2022; 4(3):665-683.

PMID: 35582307 PMC: 9094075. DOI: 10.20517/cdr.2021.36.


The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of αC-β4 loop.

Yap J, Deepak R, Tian Z, Ng W, Goh K, Foo A Sci Adv. 2021; 7(24).

PMID: 34108213 PMC: 8189578. DOI: 10.1126/sciadv.abg0390.


Protein kinases in Toxoplasma gondii.

Gaji R, Sharp A, Brown A Int J Parasitol. 2021; 51(6):415-429.

PMID: 33581139 PMC: 11065138. DOI: 10.1016/j.ijpara.2020.11.006.


The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy.

Yuan J, Dong X, Yap J, Hu J J Hematol Oncol. 2020; 13(1):113.

PMID: 32807225 PMC: 7433213. DOI: 10.1186/s13045-020-00949-4.


Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.

Degirmenci U, Wang M, Hu J Cells. 2020; 9(1).

PMID: 31941155 PMC: 7017232. DOI: 10.3390/cells9010198.


References
1.
Walsh D, PERKINS J, KREBS E . An adenosine 3',5'-monophosphate-dependant protein kinase from rabbit skeletal muscle. J Biol Chem. 1968; 243(13):3763-5. View

2.
Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A . Raf family kinases: old dogs have learned new tricks. Genes Cancer. 2011; 2(3):232-60. PMC: 3128629. DOI: 10.1177/1947601911407323. View

3.
Kornfeld K, Hom D, Horvitz H . The ksr-1 gene encodes a novel protein kinase involved in Ras-mediated signaling in C. elegans. Cell. 1995; 83(6):903-13. DOI: 10.1016/0092-8674(95)90206-6. View

4.
Taylor S, Kornev A . Yet another "active" pseudokinase, Erb3. Proc Natl Acad Sci U S A. 2010; 107(18):8047-8. PMC: 2889589. DOI: 10.1073/pnas.1003436107. View

5.
Rajakulendran T, Sahmi M, Lefrancois M, Sicheri F, Therrien M . A dimerization-dependent mechanism drives RAF catalytic activation. Nature. 2009; 461(7263):542-5. DOI: 10.1038/nature08314. View